Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Shuichi Mitsunaga

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9496-3278; OpenAlex author ID A5021407007, A5078429322. Sources: OpenAlex.

Their work

Papers
38 (first author 8, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
78
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: 3 papers · 2022: 3 papers · 2023: 5 papers · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 38

  1. Branched-chain amino acid catabolism is potentially deficient in pancreatic cancer with high-neural invasion. Last author DOI 10.1038/s41598-026-47741-x↗
  2. Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer. Co-author DOI 10.1093/jjco/hyag044↗
  3. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  4. Covered self-expandable metallic stent placement for tumor bleeding from duodenal invasion in patients with unresectable pancreatic cancer. Co-author DOI 10.1002/deo2.361↗
  5. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites. Co-author DOI 10.1016/j.pan.2024.03.015↗
  6. Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy. Co-author DOI 10.1038/s41598-024-65093-2↗
  7. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  8. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. Co-author DOI 10.1111/cas.15929↗
  9. Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1186/s13014-023-02367-5↗
  10. Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1186/s13014-023-02377-3↗
  11. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3048794/v1↗
  12. Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer. First author DOI 10.1002/cam4.4823↗
  13. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1038/s41598-022-18669-9↗
  14. [Development of Therapy for Cancer Cachexia in Pancreatic Cancer]. Co-author PMID 35851339↗
  15. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗
  16. Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. First author DOI 10.3390/cancers13194842↗
  17. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Co-author DOI 10.3390/diagnostics11071195↗
  18. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. First author DOI 10.1002/cam4.2954↗
  19. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… Co-author DOI 10.1007/s00280-020-04110-3↗
  20. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00520-020-05346-8↗
  21. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  22. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001547↗
  23. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Co-author DOI 10.1007/s10637-018-0634-5↗
  24. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO s… Co-author DOI 10.1186/s12885-019-5762-6↗
  25. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗
  26. Characterization of low active ghrelin ratio in patients with advanced pancreatic cancer. First author DOI 10.1007/s00520-018-4248-4↗
  27. Neural Invasion Spreads Macrophage-Related Allodynia via Neural Root in Pancreatic Cancer. First author DOI 10.1213/ane.0000000000002803↗
  28. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000465↗
  29. Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. Co-author DOI 10.1111/cas.13086↗
  30. Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrosp… Co-author DOI 10.1007/s40257-015-0116-x↗
  31. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. First author DOI 10.1097/mpa.0000000000000335↗
  32. [A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic … First author PMID 25812499↗
  33. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2013.174↗
  34. Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer. First author DOI 10.1002/ijc.27594↗
  35. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Co-author DOI 10.1007/s00280-011-1786-6↗
  36. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  37. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. Co-author DOI 10.1007/s00534-011-0371-z↗
  38. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Last author DOI 10.1097/mpa.0b013e3182021376↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 34 shared papers, 2011–2026 · strength 3.85
  2. Mitsuhito Sasaki · 15 shared papers, 2019–2026 · strength 2.21
  3. Hiroshi Imaoka · 13 shared papers, 2019–2026 · strength 2.02
  4. Tomoyuki Satake · 6 shared papers, 2023–2026 · strength 1.18
  5. Taro Shibuki · 6 shared papers, 2021–2026 · strength 1.14
  6. Tomonao Taira · 5 shared papers, 2023–2026 · strength 1.00
  7. Kanae Inoue · 5 shared papers, 2023–2026 · strength 1.00
  8. Atsushi Ochiai · 11 shared papers, 2012–2023 · strength 0.90
  9. Takuji Okusaka · 10 shared papers, 2011–2023 · strength 0.67
  10. Makoto Ueno · 5 shared papers, 2012–2025 · strength 0.48
  11. Hidetaka Suzuki · 4 shared papers, 2018–2022 · strength 0.46
  12. Chigusa Morizane · 8 shared papers, 2011–2021 · strength 0.44
  13. Kazuo Watanabe · 3 shared papers, 2020–2023 · strength 0.43
  14. Ai Irisawa · 3 shared papers, 2018–2022 · strength 0.37
  15. Tomofumi Miura · 4 shared papers, 2015–2021 · strength 0.35
  16. Junji Furuse · 4 shared papers, 2012–2025 · strength 0.30
  17. Akihiro Ohba · 2 shared papers, 2021–2023 · strength 0.29
  18. Hiroki Michida · 1 shared paper, 2026 · strength 0.28
  19. Masataka Amisaki · 1 shared paper, 2026 · strength 0.28
  20. Masato Ozaka · 2 shared papers, 2020–2025 · strength 0.28
  21. Hideki Ueno · 5 shared papers, 2011–2019 · strength 0.21
  22. Hideki Motobayashi · 1 shared paper, 2024 · strength 0.20
  23. Yuji Kitahata · 1 shared paper, 2024 · strength 0.20
  24. Koh Fukushi · 1 shared paper, 2024 · strength 0.20
  25. Kohei Nakata · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.